Organon & Co. (OGN) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $13.44 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away).
Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing), biosimilars (BRUKINSA, Hadlima, Renflexis), and established brands (Zetia, Singulair, Nasonex), generating $6.2 billion in 2025 revenues. Approximately 74% of revenues... Read more
Sell if holding. Analyst target reached at $13.44 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Organon & Co.
Latest news
- NEWS Organon's Supplemental Biologics License Application Gets FDA Approval For TOFIDENCE To Treat Chimeric Antigen Receptor — benzinga Jun 10, 2026 positive
- NEWS Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy — benzinga May 1, 2026 neutral
- NEWS Organon Q1 Adj. EPS $0.71 Misses $0.83 Estimate, Sales $1.460B Miss $1.484B Estimate — benzinga Apr 30, 2026 negative
- NEWS Organon Stock's Momentum Score Jumps As $11.75 Billion Sun Pharma Takeover Deal Sparks Global Pharma Consolidation Push — benzinga Apr 30, 2026 positive
- NEWS BNP Paribas Downgrades Organon to Neutral, Raises Price Target to $14 — benzinga Apr 29, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $13.44 — A.R:R is negative (-1.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.34. Score 5.7/10, moderate confidence.
Take-profit target: $13.22 (-1.6% upside). Prior stop was $13.34. Stop-loss: $13.34.
Analyst target reached - limited upside remaining; Near 52-week high (0.4% away); Leverage penalty (D/E 9.5): -1.5.
Organon & Co. trades at a P/E of 14.5 (forward 3.7). TrendMatrix value score: 8.0/10. Verdict: Sell.
13 analysts cover OGN with a consensus score of 2.5/5. Average price target: $11.
What does Organon & Co. do?Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing),...
Organon & Co. is a global healthcare company with over 70 products across women's health (NEXPLANON, NuvaRing), biosimilars (BRUKINSA, Hadlima, Renflexis), and established brands (Zetia, Singulair, Nasonex), generating $6.2 billion in 2025 revenues. Approximately 74% of revenues were generated outside the United States across 140+ countries.